Page 215 - Drug Class Review

Drug Effectiveness Review Project
Alzheimer classification: Mild-moderate
Groups similar at baseline: Yes

Health Outcome Measures:

donepezil placebo 85.9 85.4 82 83 NR NR 14.4 14.4 20.5 21.0 Primary Outcome Measures: NPI-NH Secondary Outcome Measures: MMSE; CDR-SB; PSMS Timing of assessments: Screening, baseline, and 4 week intervals throughout study No significant differences in PSMS change from baseline between DON and placebo No statistical or clinically significant differences in mean NPI-NH total scores observed between DON and placebo at any time points* Intermediate Outcome Measures: No statistically significant differences in mean MMSE change from baseline at endp

• • • •

Final Report Update 1 Authors: Tariot et al. Year: 2001 POPULATION CHARACTERISTICS: Mean age (years): Sex (% female): Ethnicity: Other germane population qualities: MMSE • NPI-NH • OUTCOME ASSESSMENT: RESULTS: Alzheimer's Drugs